N/A N=60 Conscious Sedation for Epilepsy Surgery
Epilepsy
Primary: Patients Satisfaction — 6.33; 6.45 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=107 Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department
Pain
Primary: Patients With Clinical Signs of Respiratory Depression or Sub Clinical Respiratory Depressions Measured by Capnography and Pulse Oximetry. — 22; 21 Participants
N/A N=110 Sedline EEG Guided Depth of Anesthesia
Anesthesia · Surgery
Primary: Total Average Anesthetic — 1.1890; 1.2906 percentage of sevoflurane
Phase 4 N=50 Alternative Sedation During Bronchoscopy
Sedation
Primary: Decreased Minute Ventilation — 0.736; 0.764 percentage of baseline — p=<0.0001
Early Phase 1 N=300 Sedation Regimens in GI Endoscopy
Anesthesia · Endoscopy · Colonoscopy
Primary: Pain Felt During the Procedure — 0.29; 0.30 score on a scale
N/A N=10 Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)
Conscious Sedation · Deep Sedation · Critical Care
Primary: Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus…
N/A N=11 Sedation in Patients at Risk for Upper Airway Collapse
Obstructive Sleep Apnea
Primary: Respiratory Disturbance Index — 57.52; 21.32 events per hour
N/A N=108 Comparison of Depth of Sedation Performance Between SedLine and Comparator Device During General Anesthesia
Anesthesia
Primary: Correlation of Sedation Indices Performance Across Anesthesia Range — 0.8314 Pearson r
Phase 4 N=50 Dexmedetomidine vs Propofol TIVA (Total Intravenous Anesthesia) and Interscalene Block
Shoulder Pain
Primary: Number of Participants That Need an Airway Intervention. — 0; 5 participants
Phase 2 N=8 Ultrasonic Deep Brain Stimulation During Anesthetic Sedation
Mental Function
Primary: Blood Oxygen Level Dependent (BOLD) Response to Visual Stimuli — 0.56; 0.51 percentage of BOLD signal — p=0.62
Phase 4 N=135 Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy
Procedural Sedation
Primary: Level of Sedation Throughout the Entire Procedure — 22; 9; 10; 1 participants
Phase 4 N=68 Etomidate vs. Midazolam for Sedation During ERCP
Choledocholithiasis · Cholangiocarcinoma · Pancreatitis
Primary: Number of Intervention — 1.9; 7.5 Number of intervention — p=0.05
Phase 4 N=144 A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation
Anesthesia
Primary: Respiratory Events Requiring Intervention — 17; 2 Participants
N/A N=1,771 The Emergency Department Sedation Pilot Trial
Mechanical Ventilation · Respiratory Failure
Primary: Participant Recruitment — 196; 219 Participants
N/A N=20 Validity of Bispectral Index Monitoring During Deep Sedation
Cerebral Palsy
Primary: The Correlation Between the Paired BIS Value Categories and Clinical Sedation Scores — 0.917; 0.874 correlation coefficient
Phase 3 N=50 Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy
Gastrointestinal Disease
Primary: Consumption of Rescue Patient Controlled Propofol — 42.4; 28.6 mg
Phase 4 N=114 Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy
Colonoscopy
Primary: Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure — 26; 44 Participants
Phase 4 N=798 Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Heart Disease
Primary: Number of Patients With Atrial Arrhythmia — 121; 134 Participants — p=0.34
Phase 4 N=140 Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy
Sedation · Endoscopy
Primary: Endoscopist's Satisfaction (Visual Analog Scale) About Sedation — 93; 83; 98; 87 units on a scale
N/A N=40 Probability Ramp Control of Propofol for EGD
Gastrointestinal Disease
Primary: Number of Participants Requiring Adjustment in Propofol Dosing — 16; 2 Participants
N/A N=36 Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
Glioma
Primary: Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test — 27.8; 19.1; 54.3; 21.4 seconds — p=<0.01
Phase 4 N=20 Stress During Deep Sedation With Propofol With and Without Alfentanil
Sedation
Primary: Change in Serum Catecholamines — 87; 106 mcg/ml — p=0.940
Phase 4 N=100 Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)
Sedation
Primary: Respiratory Depression (Sub-clinical and Clinical Signs) — 0.4; 0.6 percentage of participants
Phase 3 N=84 Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Endotracheal Intubation · Continuous IV Sedation · ICP Monitoring
Primary: Variability of Intracranial Pressure (ICP) — 5.66; 5.61 mmHg
N/A N=54 Ketamine Infusion and Hypoventilation
Hypoventilation
Primary: Intraoperative Hypoventilation — 1.2; 65 % time
Phase 4 N=50 Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Bronchoscopy
Primary: Hypoxemia During Maintenance — 8; 14 Participants
Phase 4 N=126 Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation
Sedation
Primary: Number of Participants With Sub-clinical Respiratory Depression and Clinical Events Associated With Respiratory Depression During the Sedation Procedure — 11; 12…
N/A N=44 Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims
Cardiac Arrest
Primary: Percentage of Seizure-positive and Seizure-negative That Were Correctly Classified by the SEDline in All Evaluated Cases — 100 percentage of seizures
Phase 2 N=15 Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients
Acute Respiratory Failure · Anxiety
Primary: Aggregate Sedative Exposure During PCS Use (up to 5 Days). — 4; 3.5 units on a scale
N/A N=16 Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine
Sleep · Sedation Complication
Primary: Difference in EEG Slow Wave Activity From Sham to In-phase Stimulation — 1.592; 1.694 Log(μV squared)